TPST Insider Trading

Insider Ownership Percentage: 4.70%
Insider Buying (Last 12 Months): $100,001.36
Insider Selling (Last 12 Months): $966,798.90

Tempest Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Tempest Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Tempest Therapeutics Share Price & Price History

Current Price: $0.71
Price Change: Price Decrease of -0.0084 (-1.17%)
As of 12/20/2024 06:40 PM ET

This chart shows the closing price history over time for TPST up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Tempest Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/12/2024Versant Venture Capital Vi, L.Major ShareholderSell387,999$1.10$426,798.90209,941View SEC Filing Icon  
8/8/2024Versant Venture Capital Vi, L.Major ShareholderSell400,000$1.35$540,000.00597,940View SEC Filing Icon  
7/3/2024Stephen R BradyCEOBuy35,000$2.11$73,850.0046,376View SEC Filing Icon  
7/2/2024Samuel WhitingInsiderBuy4,672$2.13$9,951.369,573View SEC Filing Icon  
6/28/2024Justin TrojanowskiInsiderBuy7,500$2.16$16,200.0022,168View SEC Filing Icon  
4/29/2022Thomas WoiwodeDirectorBuy2,118,644$2.36$4,999,999.842,118,644View SEC Filing Icon  
1/7/2022Thomas W. DubenskyPresidentBuy2,000$4.78$9,560.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Tempest Therapeutics (NASDAQ:TPST)

22.52% of Tempest Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TPST by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Tempest Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/16/2024Geode Capital Management LLC220,067$0.31M0.0%+42.7%0.873%Search for SEC Filing on Google Icon
11/15/2024XTX Topco Ltd23,989$34K0.0%N/A0.095%Search for SEC Filing on Google Icon
11/5/2024Empower Advisory Group LLC35,000$49K0.0%N/A0.139%Search for SEC Filing on Google Icon
10/29/2024Fullcircle Wealth LLC62,000$87K0.0%N/A0.279%Search for SEC Filing on Google Icon
8/9/2024Dimensional Fund Advisors LP25,084$55K0.0%N/A0.113%Search for SEC Filing on Google Icon
5/20/2024Virtu Financial LLC28,574$0.11M0.0%+69.2%0.129%Search for SEC Filing on Google Icon
2/15/2024MayTech Global Investments LLC10,000$44K0.0%N/A0.052%Search for SEC Filing on Google Icon
8/14/2023Rock Springs Capital Management LP536,214$0.68M0.0%-34.9%4.026%Search for SEC Filing on Google Icon
8/11/2023Sectoral Asset Management Inc.219,394$0.28M0.0%N/A1.893%Search for SEC Filing on Google Icon
2/14/2022Maven Securities LTD77,377$0.41M0.0%-39.0%1.120%Search for SEC Filing on Google Icon
11/15/2021Franklin Resources Inc.15,240$0.22M0.0%N/A0.227%Search for SEC Filing on Google Icon
11/12/2021Renaissance Technologies LLC34,104$0.49M0.0%+26.9%0.509%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.82,698$1.20M0.0%+1,581.2%1.234%Search for SEC Filing on Google Icon
11/9/2021Monashee Investment Management LLC60,000$0.87M0.2%-47.2%0.896%Search for SEC Filing on Google Icon
8/18/2021Ikarian Capital LLC89,865$1.01M0.1%N/A7.076%Search for SEC Filing on Google Icon
8/17/2021Boothbay Fund Management LLC10,477$0.12M0.0%N/A0.825%Search for SEC Filing on Google Icon
8/16/2021Maven Securities LTD106,628$1.20M0.0%N/A8.396%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC26,867$0.30M0.0%N/A2.116%Search for SEC Filing on Google Icon
8/13/2021Knott David M13,833$0.16M0.1%N/A1.089%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.61,150$0.68M0.0%N/A4.815%Search for SEC Filing on Google Icon
8/13/2021FMR LLC647,898$7.24M0.0%N/A51.016%Search for SEC Filing on Google Icon
8/12/2021Monashee Investment Management LLC113,644$1.27M0.2%N/A8.948%Search for SEC Filing on Google Icon
5/19/2021Squarepoint Ops LLC84,879$0.10M0.0%N/A0.446%Search for SEC Filing on Google Icon
5/17/2021Ikarian Capital LLC1,348,021$1.62M0.1%+897.1%7.079%Search for SEC Filing on Google Icon
5/17/2021Goldman Sachs Group Inc.20,883$25K0.0%-50.9%0.110%Search for SEC Filing on Google Icon
5/14/2021Dimensional Fund Advisors LP51,219$61K0.0%+259.3%0.269%Search for SEC Filing on Google Icon
5/14/2021Monashee Investment Management LLC500,000$0.60M0.1%N/A2.626%Search for SEC Filing on Google Icon
5/13/2021Barclays PLC42,638$51K0.0%-90.8%0.224%Search for SEC Filing on Google Icon
5/13/2021Renaissance Technologies LLC924,801$1.11M0.0%+66.0%4.856%Search for SEC Filing on Google Icon
5/13/2021Knott David M137,900$0.17M0.1%N/A0.724%Search for SEC Filing on Google Icon
5/11/2021Acadian Asset Management LLC291,230$0.35M0.0%+189.9%1.529%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.139,319$0.17M0.0%+9.8%0.732%Search for SEC Filing on Google Icon
2/24/2021Virtu Financial LLC30,755$66K0.0%N/A0.162%Search for SEC Filing on Google Icon
2/19/2021JPMorgan Chase & Co.75,264$0.16M0.0%+8,328.2%0.396%Search for SEC Filing on Google Icon
2/11/2021Barclays PLC464,390$0.99M0.0%+355.7%2.444%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC557,108$1.19M0.0%+4.1%2.932%Search for SEC Filing on Google Icon
2/9/2021Bank of New York Mellon Corp56,397$0.12M0.0%N/A0.297%Search for SEC Filing on Google Icon
11/19/2020Schonfeld Strategic Advisors LLC31,600$52K0.0%N/A0.166%Search for SEC Filing on Google Icon
11/17/2020Schonfeld Strategic Advisors LLC31,600$52K0.0%N/A0.166%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Tempest Therapeutics logo
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Read More on Tempest Therapeutics

Today's Range

Now: $0.71
Low: $0.70
High: $0.75

50 Day Range

MA: $0.95
Low: $0.70
High: $1.17

52 Week Range

Now: $0.71
Low: $0.70
High: $6.00

Volume

1,508,589 shs

Average Volume

2,052,906 shs

Market Capitalization

$31.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Tempest Therapeutics?

Tempest Therapeutics' top insider investors include:
  1. Versant Venture Capital Vi, L (Major Shareholder)
  2. Stephen R Brady (CEO)
  3. Justin Trojanowski (Insider)
  4. Samuel Whiting (Insider)
Learn More about top insider investors at Tempest Therapeutics.

Who are the major institutional investors of Tempest Therapeutics?

Tempest Therapeutics' top institutional investors include:
  1. Geode Capital Management LLC — 0.87%
  2. Fullcircle Wealth LLC — 0.28%
  3. Empower Advisory Group LLC — 0.14%
  4. XTX Topco Ltd — 0.10%
Learn More about top institutional investors of Tempest Therapeutics stock.

Which institutional investors are buying Tempest Therapeutics stock?

During the last quarter, TPST stock was purchased by institutional investors including:
  1. Geode Capital Management LLC
  2. Fullcircle Wealth LLC
  3. Empower Advisory Group LLC
  4. XTX Topco Ltd
Within the last year, these company insiders have bought Tempest Therapeutics stock:
  1. Versant Venture Capital Vi, L (Major Shareholder)
  2. Stephen R Brady (CEO)
  3. Justin Trojanowski (Insider)
Learn More investors buying Tempest Therapeutics stock.